will not receive any proceeds from the sale of ADSs by the selling shareholders.The ADSs are listed on the NASDAQ under the symbol "BGNE." The last reported sale price of the ADSs on the NASDAQ on November 16, 2016 was $36.90 per ADS.We are an "emerging growth company" as that term is used in the U.S. Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting
programs by accessing the expertise or infrastructure of strategic collaborators or by developing drug candidates with potential applications outside of our strategic focus on cancer.Risks Associated with Our Business•We are a globally focused biopharmaceutical company and have a limited operating history, which may make it difficult to evaluate our
their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.•We have entered into collaborations and may form or seek collaborations or strategic alliances or enter into additional licensing
information you receive from other public companies in which you hold equity securities.17Table of ContentsThe OfferingADSs offered by us4,336,043 ADSsADSs offered by the selling shareholders406,503 ADSsOrdinary shares outstanding immediately after this offering484,887,590 shares (494,135,543 shares if the underwriters exercise their option to purchase additional ADSs in full)Underwriters' option to purchase additional ADSsWe have granted a 30-day option to the underwriters to purchase up to an aggregate of 711,381 additional ADSs.American Depositary SharesEach ADS represents 13 ordinary shares.
includes this prospectus.DepositaryCitibank, N.A.Use of proceedsWe estimate that we will receive net proceeds from this offering of approximately $149.9 million, or $174.6 million, if the underwriters exercise their option to purchase additional ADSs in full, based upon an assumed public offering price of $36.90
otherwise indicated, all information in this prospectus reflects or assumes the following:•no issuance or exercise of share options on or after September 30, 2016; and•no exercise by the underwriters of their option to purchase additional ADSs in this offering.19Table of ContentsSUMMARY FINANCIAL DATAThe following summary financial data for the years ended December 31, 2013, 2014 and 2015 are derived from our audited
accepted accounting principles in the United States, or U.S. GAAP.20Table of ContentsYears Ended December 31,Nine Months EndedSeptember 30,20132014201520152016(unaudited)(in thousands, except share and per share data)Statements of Operations Data:Revenue$11,148$13,035$8,816$4,139$1,070Operating expensesResearch and development(13,463)(21,862)(58,250)(30,147)(69,100)General and administrative(3,143)(6,930)(7,311)(4,361)(11,760)​​​​​​​​​​​​​​​​​Total operating expenses(16,606)(28,792)(65,561)(34,508)(80,860)​​​​​​​​​​​​​​​​​Loss from operations(5,458)(15,757)(56,745)(30,369)(79,790)Interest income2401,7881,286965Interest expense(3,155)(3,552)(1,229)(840)(629)Changes in fair value of financial instruments133(2,760)(1,826)(502)(1,514)Gain on debt extinguishment—2,883———Disposal loss on available-for-sale securities——(314)(298)(1,077)Other income6948061,3099961,261Other expense(110)(206)(85)(125)(529)Income tax expense————(306)​​​​​​​​​​​​​​​​​Net loss(7,894)(18,546)(57,102)(29,852)(81,619)​​​​​​​​​​​​​​​​​Less: net loss attributable to non-controlling interests(400)(268)———Net loss attributable to ordinary shareholders$(7,494)$(18,278)$(57,102)$(29,852)$(81,619)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Loss per ordinary share attributable to ordinary shareholders, basic and diluted(1)$(0.08)$(0.18)$(0.52)$(0.28)$(0.21)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Weighted-average ordinary shares outstanding, basic and diluted91,484,52199,857,623110,597,263107,015,707383,472,372​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Comprehensive loss$(7,718)$(18,761)$(59,011)$(31,085)$(80,775)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​As of December 31,As ofSeptember 30,2013201420152016(in thousands)(unaudited)Balance Sheet Data:Cash and cash equivalents$3,926$13,898$17,869$85,532Short-term investments—30,49782,617118,086Working capital(27,300)33,81771,097180,637Total assets11,79853,621116,764235,425Long-term bank loan——6,18818,030Total liabilities48,75727,85342,44547,593Preferred shares—78,809176,084—Non-controlling interests1,767———Total shareholders' (deficit) equity(38,726)(53,041)(101,765)187,832For
staffing our company, business planning, raising capital, establishing our intellectual property portfolio and conducting preclinical studies and clinical trials of our current drug candidates, such
These losses have had and will continue to have a material adverse effect on our shareholders' deficit, financial position, cash flows and working capital.We currently do not generate revenue from product sales and may never become profitable.Our ability to generate revenue and become profitable depends upon our ability to successfully complete the development of, and obtain
revenue depends on a number of factors, including our ability to continue:•completing research regarding, and non-clinical and clinical development of, our drug candidates;•obtaining regulatory approvals and marketing authorizations for drug candidates for which we complete clinical trials;•obtaining adequate reimbursement from third-party payors, including government payors;•developing a sustainable and scalable manufacturing process for our drug candidates, including establishing and maintaining
will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our primary drug candidates: BGB-3111, BGB-A317,
potential that the FDA, CFDA, EMA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;•the number and characteristics of drug candidates that we may in-license and develop;•our ability to successfully commercialize our drug candidates;•the amount of sales and other revenues from drug candidates that we may commercialize, if any, including the selling prices for such
capabilities;•the terms and timing of any potential future collaborations, licensing or other arrangements that we may establish;•cash requirements of any future acquisitions and/or the development of other drug candidates;•the costs of operating as a public company;•the cost and timing of completion of commercial-scale outsourced manufacturing activities;•the time and cost necessary to respond to technological and market developments; and•the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.Until
require us to relinquish rights to our technologies or drug candidates.We may seek additional funding through a combination of equity offerings, debt financings, collaborations and licensing arrangements.
dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amount we would receive.Our investments are subject to risks that could result in losses.We had cash and cash equivalents of $17.9 million and $85.5 million and short-term investments of $82.6 million
including:•the size and nature of the patient population;•the patient eligibility criteria defined in the protocol;•the size of the study population required for analysis of the trial's primary endpoints;•the proximity of patients to trial sites;•the design of the trial;•our ability to recruit clinical trial investigators with the appropriate competencies and experience;•competing clinical trials for similar therapies or other new therapeutics;•clinicians' and patients' perceptions as to the potential advantages and side effects of the drug candidate being studied in relation
competitors to bring drugs to market before we do and impair our ability to commercialize our drug candidates and may harm our business and results of operations.Risks Related to Obtaining Regulatory Approval for Our Drug CandidatesThe regulatory approval processes of the FDA, CFDA, EMA and other comparable regulatory authorities
FDA, CFDA, EMA or a comparable regulatory authority may require more information, including additional preclinical or clinical data, to support approval, which may delay or prevent
may result from many factors, including:•our inability to obtain sufficient funds required for a clinical trial;•regulatory requests for additional analyses, reports, data, non-clinical and preclinical studies and clinical trials;•regulatory questions regarding interpretations of data and results and the emergence of new information regarding our drug candidates
regulatory entity, to suspend or terminate clinical trials at any time for safety issues or for any other reason;•failure to demonstrate a benefit from using a drug or biologic;•lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions;•our inability to reach agreements on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the
terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;•our inability to obtain approval from IRBs or ethics committees to conduct clinical trials at their respective sites;•manufacturing issues, including problems with manufacturing or timely obtaining from third parties sufficient quantities of a drug
or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.Undesirable adverse events caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical
In addition, even if one or more of our drug candidates qualify as Breakthrough Therapies, the FDA may later decide that such drug candidates no longer meet the conditions for qualification.36Table of ContentsWe may seek orphan drug exclusivity for some of our drug candidates, and we may be unsuccessful.Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient
will not be able to commercialize our drug candidates, and our ability to generate revenue will be materially impaired.We currently do not have any drug candidates that have gained regulatory approval for sale in the United States, European Union, China
Our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully commercialize drug candidates in a timely
trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that the drug candidate is safe and effective for use for that target indication and that the manufacturing
when this approval process will be changed is still subject to further policies to be issued by the CFDA and is currently uncertain.•The process to develop, obtain regulatory approval for and commercialize drug candidates is long, complex and costly both inside and
new drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.Coverage and reimbursement may be limited or unavailable in certain market segments for our drug
regulatory approval of and commercialize our drug candidates and affect the prices we may obtain.In the United States, PRC, European Union and some other jurisdictions, there have been a number of legislative and regulatory changes
negotiated prices;•extension of manufacturers' Medicaid rebate liability;•expansion of eligibility criteria for Medicaid programs;•expansion of the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program;•new requirements to report financial arrangements with physicians and teaching hospitals;•a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and•a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
and distribution efforts may increase our expenses or divert our management's attention from the acquisition or development of drug candidates;•changes in a specific country's or region's political and cultural climate or economic condition;•differing regulatory requirements for drug approvals and marketing internationally;•difficulty of effective enforcement of contractual provisions in local jurisdictions;•potentially reduced protection for intellectual property rights;•potential third-party patent rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation or political instability, particularly in non-U.S. economies and markets;•compliance with tax, employment, immigration and labor laws for employees traveling abroad;•the effects of applicable non-U.S. tax structures and potentially adverse tax consequences;•currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to
position by filing patent applications in the United States, the PRC and other countries related to novel technologies and drug candidates that we consider are important to our business.
be able to block our ability to develop and commercialize the applicable drug candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held
further develop our drug candidates or bring them to market and generate product sales revenue, which would harm our business prospects, financial condition and results of operations.Risks Related to Our Industry, Business and OperationsOur future success depends on our ability to retain the Chairman of our scientific advisory board
Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including:•efforts to develop an international sales, marketing and distribution organization may increase our expenses, divert our management's
These risks could in the future have a material adverse effect on our business, financial condition and results of operations.Any failure to comply with PRC regulations regarding our employee equity incentive plans may subject
purposes under the EIT Law and be subject to PRC tax on our worldwide taxable income at a rate of 25%," dividends paid on our ordinary shares or ADSs, and any gain realized from the transfer of our
established outside China are considered a PRC resident enterprise, holders of the ADSs or ordinary shares would be able to claim the benefit of income tax treaties or agreements entered into between
business activities outside of the PRC or pay dividends in foreign currencies to our shareholders, including holders of the ADSs. Foreign exchange transactions under the capital account remain subject
activities;•any adverse changes to our relationship with manufacturers or suppliers;•the results of our testing and clinical trials;•the results of our efforts to acquire or license additional drug candidates;•variations in the level of expenses related to our existing drug candidates or preclinical and clinical development programs;•any intellectual property infringement actions in which we may become involved;•announcements concerning our competitors or the pharmaceutical industry in general;•achievement of expected product sales and profitability;•manufacture, supply or distribution shortages;84Table of Contents•variations in our results of operations;•announcements about our earnings that are not in line with analyst expectations, the risk of which is enhanced because it is our
ventures or capital commitments;•press reports, whether or not true, about our business;•additions to or departures of our management;•fluctuations of exchange rates between the RMB and the U.S. dollar;•release or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares or ADSs;•sales or perceived potential sales of additional ordinary shares or ADSs;•sales of the ADSs by us, our executive officers and directors or our shareholders in the future;•general economic and market conditions and overall fluctuations in the U.S. equity markets;•changes in accounting principles;•changes or developments in the PRC or global regulatory environment; and•the outcome of proceedings recently instituted by the SEC against five PRC-based accounting firms, including the affiliate of our
sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.Upon completion of this offering, assuming the underwriters do not exercise their option to purchase additional shares, 68.1% of our outstanding ordinary shares immediately after this
directors authorizes the issuance of preferred shares, the market price of the ADSs may fall and the voting and other rights of the holders of our ordinary shares may be materially and adversely
prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.The depositary for the ADSs is entitled to charge holders fees for various services, including
other shareholders, including the holders of the ADSs. In addition, these persons could divert business opportunities away from us to themselves or others.We have incurred increased costs as a result of operating as a public company, and our management
technology;•our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;•cost associated with defending against intellectual property infringement, product liability and other claims;•regulatory developments in the United States, China, the United Kingdom, the European Union and other jurisdictions;•the accuracy of our estimates regarding expenses, future revenues, capital requirements and our need for additional financing;•the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;•our ability to maintain and establish collaborations or obtain additional grant funding;•the rate and degree of market acceptance of our drug candidates;•developments relating to our competitors and our industry, including competing therapies;•the size of the potential markets for our drug candidates and our ability to serve those markets;•our ability to effectively manage our anticipated growth;•our ability to attract and retain qualified employees and key personnel;95Table of Contents•our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;•statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance;•our expected use of proceeds of this offering;•the future trading price of the ADSs and impact of securities analysts' reports on these prices; and•other risks and uncertainties, including those listed under the caption "Risk Factors" and elsewhere in this prospectus and the
ordinary shares are immobilized on account of a shareholders' meeting or a payment of dividends.•obligations to pay fees, taxes and similar charges; or•restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit.The